Acta Neuropharmacologica››2013,Vol. 3››Issue (6): 44-47.
Previous ArticlesNext Articles
WANG Jin
Online:2013-12-26Published:2014-06-27About author:王金，男，讲师，硕士；研究方向：中药新药研究开发；Tel：+86-0313-4029305；E-mail：wangjinzym@163.comSupported by:
河北省卫生厅资助项目（No.20110173），河北省教育厅资助项目（No.Z2011304）
CLC Number:
WANG Jin.Non-motor Symptoms of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2013, 3(6): 44-47.
| [1] Sara Varanese, Zoe Birnbaum, Roger Rossi, et al. Treatment of advanced Parkinson’s disease[J].Parkinsons Dis, 2011, 2010: 480260. [2] Cynthia L Commella. Sleep disturbances in Parkinson’s disease[J] .Curr Neurol Neurosci Rep, 2003, 10(3):173–180. [3] I Eisensehr, R linke, S Noachtar, et al. Reduced striatal dopamine transports in idiopathic rapid eye movement sleep behaviour disorder.comparasion with parkinson’s disease[J]. Brain, 2000, 123(Pt6): 1155-1160. [4] B F Boeve, M H Silber, J E Parisi, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism[J]. Neurology, 2003, 61(1): 40–45. [5] J F Gagnon, M A Bedard, M L Fantini, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease [J]. Neurology, 2002, 59(4):585–589. [6] R D Abbott, G W Ross, L R White, et al. Excessive daytime sleepiness and the future risk of Parkinson’s disease [J]. Mov Disord, 2005, 20(10):S101. [7] Thomas Müller. Drug therapy in patients with Parkinson’s disease [J]. Translational Neurodegeneration, 2012, 1:10. [8] Sze-Ee Soh, Meq E Morris, Jennifer L McGinley. Determinants of health-related quality of life in Parkinson’s disease: a systematic review [J].Parkinsonism Relat Disord, 2011, 17(1):1-9. [9] J Schwarz, P Odin, C Buhmann, et al. Depression in Parkinson’s disease [J]. J Neurol, 2011, 258(suppl 2):S336-S338. [10] Laura Marsh. Neuropsychiatric aspects of Parkinson’s disease [J]. Psychosmatics, 2000, 41(1):15-23. [11] 周晓雯，苏朝芬，罗焕敏. 线粒体与神经退行性疾病[J].神经药理学报，2011，1(3)：41-46. [12] 薛占霞，彭亮. 情感性精神障碍疾病治疗药物的研究现状[J].神经药理学报，2011，1(3)：55-64. [13] Ziemssen Tjalf, Heinz Reichmann. Non-motor dysfunction in Parkinson’s disease [J]. Parkinsonism related disorder, 2007, 13(6):323332. [14] I H Richard, R B Schiffer, R Kurlan. Anxiety and Parkinson’s disease [J]. J Neuropsychiatry Clin Neurosci, 1996, 8:383-392. [15] Manmohan Mehndiratta, Rohit K Garg, Sanjay Pandey. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity [J]. J Assoc Physicians India, 2011, 59: 302-308. [16] E C Lauterbach, R C Duvoisin. Anxiety disorders in familial parkinsonism [J]. Am J Psychiatry, 1992, 148(2):274. [17] Jennifer G Goldman. New thoughts on thought disorders in Parkinson’s disease: review of current research strategies and challenges [J]. Parkinsons Dis, 2011, 2011:675630. [18] 王新，于谭方，王平. 帕金森病患者非运动症状的研究进展 [J].国际神经病学神经外科杂志，2011（38）2:139-142. [19] Angie A Kehagia, Roger A Baker, Trevor W Robbins. Neuropsychological and clinical heterogeneity of congnitive impariment and dementia in patients with Parkinson’s disease [J]. Lancet Neurol, 2010, 9(12): 1200-1213. [20] Murat Emre. Demetia associated with Parkinson’s disease [J]. Lancet Neurol, 2003, 2(4): 229–237. [21] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol, 2012, 44(2):415-424. [22] Michael S Okun, Benjamin L Walter, William M McDonald, et al. Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson’s disease [J]. Arch Neurol, 2002, 59(11):1750-1753. [23] Francesca Romana Pezzella, Carlo Colosimo, Nicola Vanacore, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease [J].Mov Disord, 2005, 20(1):77-81. [24] R D Abbott, H Petrovitch, L R White, et al. Frequency of bowel movements and future risk of Parkinson’s disease[J]. Neurology, 2001, 57(3):456-462. [25] Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson’s disease [J].Lancet, 1996, 1:1366-1369. [26] W Poewe. Nonmotor symptoms in Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders [M]. 5th. Philadelphia: Lippincott Williams and Wilkins, 2007:67-76. [27] Andrew Siderowf, Danna Jdennings, James Connolly, et al. Risk factors for Parkinson’s disease and impaired olfaction in relatives of patients with Parkinson’s disease[J]. Mov Disord, 2007, 22(15):2249-2255. [28] G Webster Ross, Helen Petrovitch, Robert D Abbott, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease [J]. Ann Neurol, 2008, 63(2):167-173. |
| [1] | XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8. |
| [2] | SUN Li-cong, ZHANG Dan-shen.Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37. |
| [3] | WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si.Current Situation and Prospect of Alzeimer’s Disease Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42. |
| [4] | ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia.Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64. |
| [5] | HAI Ji-tao, LUO Huan-min.Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64. |
| [6] | ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong.Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7. |
| [7] | YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong.Research Progress in Drug Treatment of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53. |
| [8] | ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia.Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46. |
| [9] | YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64. |
| [10] | ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20. |
| [11] | 王奇.Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease[J]. Acta Neuropharmacologica, 2018, 8(5): 71-72. |
| [12] | CUI Su-ying, SONG Jin-zhi, CUI Xiang-yu, HU Xiao, DING Hui, YE Hui, ZHANG Yong-he.Intracerebroventricular Streptozocin-induced Alzheimer’s Disease-like Sleep Disorders: Role of the GABAergic System in the Parabrachial Complex[J]. Acta Neuropharmacologica, 2018, 8(5): 96-97. |
| [13] | YU Li-li1，2，XU Li1，WANG Yi-nuo1，XUE Lu-ning1，Gou Ji-wei1，LI Hong-bo1，HOU Xue-qin1*，ZHANG Han-ting1*.Effects of Osthole on Learning and Memory and the Estrogen Pathway in Ovariectomized Rats[J]. Acta Neuropharmacologica, 2018, 8(4): 7-8. |
| [14] | SHEN li-xia1，LIU Liang-liang1，ZHANG Ming1，LIU Yang1，ZHANG Dan-shen 2*.Research of Quercetin’s Estrogen-Like Action on Central Nervous System and Its Mechanisms[J]. Acta Neuropharmacologica, 2018, 8(4): 23-25. |
| [15] | WANG Hao1, ZHANG Fang-fang1, FU Hua-rong1, ZHOU Yan-meng1, LIU Xin1, HOU Xue-qin 1, HU Wei2, Rolf Hansen2, XU Ying3, James O’Donnell3, ZHANG Han-ting1,2.Targeting PDE4 for Alzheimer’s Disease and Alcoholism: An implication in Alcohol-Related Dementia?[J]. Acta Neuropharmacologica, 2018, 8(4): 39-41. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
